EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chimeric lipoproteins for leptospirosis vaccine: immunogenicity and protective potential

Rafael Carracena de Souza Tapajóz, Francisco Denis Souza Santos, Natasha Rodrigues de Oliveira, Mara Andrade Colares Maia, Amilton Clair Pinto Seixas Neto, Laura de Vargas Maiocchi, Pedro Henrique Filgueiras Coelho Souza, Thaís Larré Oliveira, Odir Antônio Dellagostin

Applied Microbiology and Biotechnology · 2024-12 · 108 (1)

DOI: 10.1007/s00253-024-13196-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 22.07.2024. Verfasst von Rafael Carracena de Souza Tapajóz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Center, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil. Hauptthemen laut MEDLINE: Leptospirosis, Lipoproteins, Bacterial Vaccines, Antibodies, Bacterial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leptospirosis, a neglected zoonotic disease, is caused by pathogenic spirochetes belonging to the genus Leptospira and has one of the highest morbidity and mortality rates worldwide. Vaccination stands out as one of the most effective preventive measures for susceptible populations. Within the outer membrane of Leptospira spp., we find the LIC12287, LIC11711, and LIC13259 lipoproteins. These are of interest due to their surface location and potential immunogenicity. Thorough examination revealed the conservation of these proteins among pathogenic Leptospira spp.; we mapped the distribution of T- and B-cell epitopes along their sequences and assessed the 3D structures of each protein. This information aided in selecting immunodominant regions for the development of a chimeric protein. Through gene synthesis, we successfully constructed a chimeric protein, which was subsequently expressed, purified, and characterized. Hamsters were immunized with the chimeric lipoprotein, formulated with adjuvants aluminum hydroxide, EMULSIGEN®-D, Sigma Adjuvant System®, and Montanide™ ISA206VG. Another group was vaccinated with an inactivated Escherichia coli bacterin expressing the chimeric protein. Following vaccination, hamsters were challenged with a virulent L. interrogans strain. Our evaluation of the humoral immune response revealed the production of IgG antibodies, detectable 28 days after the second dose, in contrast to pre-immune samples and control groups. This demonstrates the potential of the chimeric protein to elicit a robust humoral immune response; however, no protection against challenge was achieved. While this study provides valuable insights into the subject, further research is warranted to identify protective antigens that could be utilized in the development of a leptospirosis vaccine. Key points • Several T- and B-cell epitopes were identified in all the three proteins. • Four different adjuvants were used in vaccine formulations. • Immunization stimulated significant levels of IgG2/3 in vaccinated animals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeptospirosisLipoproteinsBacterial VaccinesAntibodies, BacterialAnimalsCricetinaeEpitopes, B-LymphocyteRecombinant Fusion ProteinsAdjuvants, ImmunologicImmunoglobulin GEpitopes, T-LymphocyteLeptospira interrogansBacterial Outer Membrane ProteinsVaccinationImmunity, HumoralLeptospiraImmunogenicity, Vaccine

Stichwörter der Autor:innen

LeptospiraAdjuvantsChimeric proteinRecombinant bacterinRecombinant inactivated E. coli vaccineRecombinant subunit vaccine

Substanzen

LipoproteinsBacterial VaccinesAntibodies, BacterialEpitopes, B-LymphocyteRecombinant Fusion ProteinsAdjuvants, ImmunologicImmunoglobulin GEpitopes, T-LymphocyteBacterial Outer Membrane Proteins

Autor:innen und Institutionen

  • Biotechnology Center, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.
  • Department of Microbiology and Parasitology, Institute of Biology, Federal University of Pelotas, Pelotas, RS, Brazil.
  • Biotechnology Center, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil. odirad@gmail.com.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Tapajóz, R. C. S., Santos, F. D. S., de Oliveira, N. R., Maia, M. A. C., Seixas Neto, A. C. P., Maiocchi, L. V., Souza, P. H. F. C., Oliveira, T. L., & Dellagostin, O. A. (2024). Chimeric lipoproteins for leptospirosis vaccine: immunogenicity and protective potential. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-024-13196-1

Vancouver

Tapajóz RCS, Santos FDS, de Oliveira NR, Maia MAC, Seixas Neto ACP, Maiocchi LV, et al. Chimeric lipoproteins for leptospirosis vaccine: immunogenicity and protective potential. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-024-13196-1

BibTeX
@article{Tapajz2024,
  author = {Tapajóz, Rafael Carracena de Souza and Santos, Francisco Denis Souza and de Oliveira, Natasha Rodrigues and Maia, Mara Andrade Colares and Seixas Neto, Amilton Clair Pinto and Maiocchi, Laura de Vargas and Souza, Pedro Henrique Filgueiras Coelho and Oliveira, Thaís Larré and Dellagostin, Odir Antônio},
  title = {Chimeric lipoproteins for leptospirosis vaccine: immunogenicity and protective potential},
  journal = {Applied Microbiology and Biotechnology},
  year = {2024},
  volume = {108},
  number = {1},
  doi = {10.1007/s00253-024-13196-1}
}
Kostenlos starten →